Login to Your Account



Earnings Roundup


Monday, November 7, 2011

• Acorda Therapeutics Inc., of Hawthorne, N.Y., reported third quarter 2011 revenues of $93 million, edging ahead of analyst estimates of $91 million. Revenues from Ampyra (dalfampridine) for multiple sclerosis mobility were $54.7 million, also just ahead of expectations. Acorda's GAAP net income for the third quarter was $18.9 million, or 47 cents per share. The firm had $268.8 million in cash, equivalents and investments as of Sept. 30. Analysts were pleased to see Ampyra keeping pace with expectations, and shares (NASDAQ:ACOR) gained $2.63, or 13 percent, to close at $23.08 on Friday.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription